337 related articles for article (PubMed ID: 15335289)
1. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
Scharfetter J
Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
[TBL] [Abstract][Full Text] [Related]
2. Dopamine receptor polymorphisms and drug response in schizophrenia.
Scharfetter J
Pharmacogenomics; 2001 Aug; 2(3):251-61. PubMed ID: 11535113
[TBL] [Abstract][Full Text] [Related]
3. Association study between antipsychotics- induced restless legs syndrome and polymorphisms of dopamine D1, D2, D3, and D4 receptor genes in schizophrenia.
Kang SG; Lee HJ; Choi JE; Park YM; Park JH; Han C; Kim YK; Kim SH; Lee MS; Joe SH; Jung IK; Kim L
Neuropsychobiology; 2008; 57(1-2):49-54. PubMed ID: 18451638
[TBL] [Abstract][Full Text] [Related]
4. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
5. Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.
Wu S; Xing Q; Gao R; Li X; Gu N; Feng G; He L
Neurosci Lett; 2005 Mar; 376(1):1-4. PubMed ID: 15694263
[TBL] [Abstract][Full Text] [Related]
6. [Correlation between the effectiveness of atypical antipsychotics and dopamine D3 receptor polymorphism in schizophrenia].
Szekeres G; Juhász A; Kéri S; Rimanóczy A; Szendi I; Szabó Z; Janka Z
Ideggyogy Sz; 2002 Nov; 55(11-12):377-81. PubMed ID: 12632798
[TBL] [Abstract][Full Text] [Related]
7. Polymorphisms of dopamine D2-like (D2, D3, and D4) receptors in schizophrenia.
Ohara K; Nakamura Y; Xie DW; Ishigaki T; Deng ZL; Tani K; Zhang HY; Kondo N; Liu JC; Miyasato K; Ohara K
Biol Psychiatry; 1996 Dec; 40(12):1209-17. PubMed ID: 8959285
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacogenetics and treatment response in schizophrenia].
Moulier V; Januel D
Encephale; 2007 Dec; 33(6):954-64. PubMed ID: 18789788
[TBL] [Abstract][Full Text] [Related]
9. CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine.
Aklillu E; Kalow W; Endrenyi L; Harper P; Miura J; Ozdemir V
Pharmacogenet Genomics; 2007 Nov; 17(11):989-93. PubMed ID: 18075468
[TBL] [Abstract][Full Text] [Related]
10. [Family based association study of DRD1, DRD2, DRD3, DRD4, DAT, COMT gene polymorphism in schizophrenia].
Paweł K; Hauser J; Skibińska M; Szczepankiewicz A; Dmitrzak-Weglarz M; Gorzkowska K; Pawlak J; Czerski PM
Psychiatr Pol; 2010; 44(3):405-13. PubMed ID: 20672519
[TBL] [Abstract][Full Text] [Related]
11. Variants in the DRD2 locus and antipsychotic-related prolactin levels: A meta-analysis.
Miura I; Zhang JP; Hagi K; Lencz T; Kane JM; Yabe H; Malhotra AK; Correll CU
Psychoneuroendocrinology; 2016 Oct; 72():1-10. PubMed ID: 27333159
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics as a tool in the therapy of schizophrenia.
Wilffert B; Zaal R; Brouwers JR
Pharm World Sci; 2005 Feb; 27(1):20-30. PubMed ID: 15861931
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Arranz MJ; de Leon J
Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphisms in the dopamine-2 receptor (DRD2), dopamine-3 receptor (DRD3), and dopamine transporter (SLC6A3) genes in schizophrenia: Data from an association study.
Sáiz PA; García-Portilla MP; Arango C; Morales B; Arias B; Corcoran P; Fernández JM; Alvarez V; Coto E; Bascarán MT; Bousoño M; Fañanas L; Bobes J
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):26-31. PubMed ID: 19766158
[TBL] [Abstract][Full Text] [Related]
15. DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.
Lencz T; Robinson DG; Xu K; Ekholm J; Sevy S; Gunduz-Bruce H; Woerner MG; Kane JM; Goldman D; Malhotra AK
Am J Psychiatry; 2006 Mar; 163(3):529-31. PubMed ID: 16513877
[TBL] [Abstract][Full Text] [Related]
16. Influence of DRD2 polymorphisms on the clinical outcomes of patients with schizophrenia.
Zahari Z; Teh LK; Ismail R; Razali SM
Psychiatr Genet; 2011 Aug; 21(4):183-9. PubMed ID: 21206399
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
[TBL] [Abstract][Full Text] [Related]
18. D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.
Zhang JP; Lencz T; Malhotra AK
Am J Psychiatry; 2010 Jul; 167(7):763-72. PubMed ID: 20194480
[TBL] [Abstract][Full Text] [Related]
19. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia.
Miura I; Takeuchi S; Katsumi A; Mori A; Kanno K; Yang Q; Mashiko H; Numata Y; Niwa S
J Clin Psychopharmacol; 2012 Feb; 32(1):106-9. PubMed ID: 22198450
[TBL] [Abstract][Full Text] [Related]
20. The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.
Suzuki A; Kondo T; Mihara K; Yasui-Furukori N; Ishida M; Furukori H; Kaneko S; Inoue Y; Otani K
Pharmacogenetics; 2001 Aug; 11(6):545-50. PubMed ID: 11505224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
